In a mouse model of NAFLD, administration of butyrate reversed the reduction of GLP-1R and led to upregulation of hepatic AMPK phosphorylation and insulin receptor expression in treated mice. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.